Looking for a comprehensive resource on cervical cancer? CDC’s fact sheet explains cervical cancer in plain language to help everyone understand screening and risk factors. In addition, CDC’s cervical cancer awareness resources are available here and HPV vaccination resources are available here.
The National HPV Vaccination RoundTable Late 2016 brought exciting developments for HPV cancer prevention, with the ACIP recommending an updated 2-dose HPV vaccination schedule. This news was well received by members of the National HPV Vaccination Roundtable, ...
Looking for a comprehensive resource on cervical cancer? CDC’s fact sheet explains cervical cancer in plain language to help everyone understand screening and risk factors. In addition, CDC’s cervical cancer awareness resources are available here and HPV vaccination resources are available here.
Researchers from Yale University have developed a new model to account for HPV transmission and cervical cancer progression to determine that widespread, coordinated use of nonavalent HPV vaccination would provide the same health benefits at the same or lower cost. The study, published in Proceedings of the National Academy of Science in March, found that nonavalent vaccination could decrease cervical cancer incidence by 73%, compared to a 63% reduction in incidence from earlier generation HPV vaccines. The greatest health benefits ...
In June, Cervical Cancer Free Coalition submitted a written testimony to Congress in support of cervical cancer activities. Read the full testimony here: Testimony for Senate SFOPS from CCFC!
A recent systematic review published in Lancet Global Health in July found global disparities in age-specific vaccination coverage rates between 2006 and 2014. Among the 118 million women targeted for HPV vaccination programs, only 1% were from low or low-middle income countries. More women 10-20 years old received the full vaccine course in developed regions (33.6%) than less developed regions (2.7%). The high cost of the vaccine and programmatic issues were major obstacles to introducing the vaccine in less developed ...
Researchers from the Center of Disease Control and Prevention (CDC) observed an increase in HPV vaccine coverage for both boys and girls ages 13-17 years old. The finding, published in the CDC’s Morbidity and Mortality Weekly Report (MMWR) in August 2016, noted that the percent of boys 13-17 years old who received at least 1 dose of the HPV vaccine increased 8% between 2014 and 2015. Vaccination also increased by 2.8% among girls 13-17 years old, during that same timeframe. ...
The American Society of Clinical Oncology (ASCO) recently convened a multidisciplinary panel of health care and patient advocacy experts to provide evidence-based recommendations on secondary prevention of cervical cancer around the world. Their report, entitled “Secondary Prevention of Cervical Cancer: Resource-Stratified Clinical Practice Guideline”, was published in the Journal of Global Oncology in October 2016. The guidelines cover recommended age ranges for and frequency of testing, methods of testing, treatment options, and screening practices in four resource settings: maximal, ...
The American Society of Clinical Oncology (ASCO) recently convened a multidisciplinary panel of health care and patient advocacy experts to provide evidence-based recommendations on secondary prevention of cervical cancer around the world. Their report, entitled “Secondary Prevention of Cervical Cancer: Resource-Stratified Clinical Practice Guideline”, was published in the Journal of Global Oncology in October 2016. The guidelines cover recommended age ranges for and frequency of testing, methods of testing, treatment options, and screening practices in four resource settings: maximal, ...
Following its meeting in late October, the CDC’s Advisory Committee on Immunization Practices (ACIP) has recommended that patients ages 11-12 receive two doses of the HPV vaccine. The recommendation was made after a comprehensive literature review, finding that a two-dose schedule for younger adolescents (9-14 years old) produced a comparable immune response to that produced through the 3-dose schedule for young adults 16-26 years old. Those who begin the series at later ages (>14 years) are still recommended to receive ...
The American Society of Clinical Oncology (ASCO) has published its first resource-stratified guidelines on the clinical practice of invasive cervical cancer. The report, published in the Journal of Global Oncology (May, 2016), classifies the new recommendations into four tiers: basic, limited, enhanced, and maximal.
Some of the key recommendations are:
In basic settings where patients cannot be treated with radiation therapy, extrafascial hysterectomy either alone or after chemotherapy may be an option for women with stage IA1 to IVA cervical cancer. Concurrent ...